Mineralys Therapeutics Files 8-K
Ticker: MLYS · Form: 8-K · Filed: May 31, 2024 · CIK: 1933414
Sentiment: neutral
Topics: filing, financials, exhibits
Related Tickers: MLYS
TL;DR
MLYS filed an 8-K with exhibits, nothing major to see here.
AI Summary
Mineralys Therapeutics, Inc. filed an 8-K on May 31, 2024, to report financial statements and exhibits. The filing does not contain specific financial figures or material events beyond the standard reporting of exhibits.
Why It Matters
This filing indicates Mineralys Therapeutics is fulfilling its regulatory reporting requirements by submitting financial statements and exhibits.
Risk Assessment
Risk Level: low — The filing is a routine submission of financial statements and exhibits, not indicating any new risks or material events.
Key Players & Entities
- Mineralys Therapeutics, Inc. (company) — Registrant
- May 31, 2024 (date) — Date of report
FAQ
What is the primary purpose of this 8-K filing for Mineralys Therapeutics, Inc.?
The primary purpose of this 8-K filing is to report financial statements and exhibits as of May 31, 2024.
What is the exact date of the earliest event reported in this filing?
The date of the earliest event reported is May 31, 2024.
What is the state of incorporation for Mineralys Therapeutics, Inc.?
Mineralys Therapeutics, Inc. is incorporated in Delaware.
What is the principal executive office address for Mineralys Therapeutics, Inc.?
The principal executive office is located at 150 N. Radnor Chester Road, Suite F200, Radnor, Pennsylvania 19087.
Does this filing disclose any specific new material events or financial results?
No, this filing primarily reports financial statements and exhibits and does not disclose specific new material events or detailed financial results beyond what is standard for such a filing.
Filing Stats: 508 words · 2 min read · ~2 pages · Grade level 10.4 · Accepted 2024-05-31 16:06:07
Key Financial Figures
- $0.0001 — ch registered Common Stock, par value $0.0001 per share MLYS The Nasdaq Stock Marke
Filing Documents
- mlys-20240531.htm (8-K) — 28KB
- mlys20240531exhibit51.htm (EX-5.1) — 14KB
- image_0.jpg (GRAPHIC) — 12KB
- 0001933414-24-000024.txt ( ) — 191KB
- mlys-20240531.xsd (EX-101.SCH) — 2KB
- mlys-20240531_lab.xml (EX-101.LAB) — 23KB
- mlys-20240531_pre.xml (EX-101.PRE) — 13KB
- mlys-20240531_htm.xml (XML) — 3KB
01. Financial Statements and Exhibits
Item 9.01. Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 5.1 Opinion of Faegre Drinker Biddle & Reath LLP related to the ATM Prospectus Supplement 23.1 Consent of Faegre Drinker Biddle & Reath LLP (included in Exhibit 5.1) 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Dated: May 31, 2024 MINERALYS THERAPEUTICS, INC. By: /s/ Adam Levy Name: Adam Levy Title: Chief Financial Officer and Secretary